Viatris and Medical Learning Hub welcome you to the live CME on Enhance meetings III : The Courtroom Series ; an interactive, debate-style program that uses a courtroom format to simplify key clinical dilemmas in Hepatitis B management. Through two case dockets, expert faculty present opposing viewpoints supported by polling, rebuttals, and focused discussions.
The session explores critical questions on the duration of NA therapy and the approach to universal versus selective treatment in HBsAg-positive patients, followed by an interactive Q&A. This format delivers clear, evidence-based insights and enhances decision-making in HBV care.
To know more click Agenda.
We wish you a great learning experience!
We thank Mylan Pharmaceuticals Private Limited, a Viatris Company for supporting us in the webinar
|
Topic
|
Details
|
Faculty
|
Time slot
|
|
Welcome and Introduction
|
|
Viatris/MLH
|
5 min
|
|
Context to Case docket 1
|
|
Viatris
|
5 min
|
|
Courtroom Case docket 1 - Duration
of NA Therapy – with polling
|
Position A - Continue indefinitely
to suppress HBV DNA & reduce HCC risk
|
HCP 1
HCP 2
|
20min
|
|
Position B - Stop after years of
suppression (esp. with HBeAg seroconversion, low HBsAg, or APASL criteria)
|
|
Rebuttal
|
Position A
|
HCP 1
|
5 min
|
|
Context to Case docket 2
|
|
Viatris
|
5 min
|
|
Courtroom Case docket 2 - Universal
Treatment vs. Selective – with Polling
|
Position A - Treat all HBsAg+
patients to reduce HCC/transmission risk
|
HCP 1
HCP 2
|
20 min
|
|
Position B - Treat only those with
active disease or cirrhosis
|
|
Rebuttal
|
Position A
|
HCP 1
|
5 min
|
|
Qn A
|
|
All Faculty
|
10 min
|
|
Vote of Thanks
|
|
Viatris / MLH
|
5 min
|
